Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Melanoma/Skin Cancer
Would you ever consider SBRT for de novo cutaneous squamous cell carcinoma?
Is there any data to support it? What dose/fractionation would you consider?
Answer from: Radiation Oncologist at Community Practice
No role for SBRT.
Sign in or Register to read more
12444
Related Questions
What ENI/lymph node stations would you treat for a locally advanced SCC of the thumb?
Do you obtain MRI for cutaneous SCC with microscopic PNI to assess for gross perineural tumor spread?
In patients with multiple basal cell carcinoma lesions on vismodegib, would you hold vismodegib while delivering radiation therapy to one locally advanced BCC lesion that was not amenable to surgery?
How would you treat locally advanced melanoma of the scalp with several in transit lesions and a metastatic lesion to the parotid if the patient is progressing on immunotherapy such as pembrolizumab?
How would you manage a large area of multiple, recurrent cutaneous squamous cell carcinomas of the scalp with ulcerations and non-healing areas despite cryotherapy, multiple Mohs procedures, and 5-FU?
Would you consider adjuvant radiation for a patient with recurrent pelvic node melanoma s/p immunotherapy and pelvic lymph node dissection with complete pathological response (only necrotic tissue; no viable melanoma)?
What are the indications for postoperative radiation for extramammary Paget's disease?
How would you manage a cardiac metastasis from Merkel cell carcinoma?
How would you palliate a large, symptomatic vaginal melanoma recurrence with limited small pelvic lymph node metastases?
In patients with HER-2 positive breast cancer on pertuzumab/trastuzumab with newly developed asymptomatic brain metastases only, do you wait 3 weeks after administration of the targeted therapy to deliver SRS?